NASDAQ:BDSX

Biodesix (BDSX) Stock Forecast, Price & News

$1.49

-0.05 (-3.25%)

(As of 09/28/2023 ET)

Compare

Today's Range: $1.47
▼
$1.52
50-Day Range: $1.04
▼
$1.74
52-Week Range: $0.96
▼
$2.53

Volume: 15,568 shs
Average Volume: 85,178 shs
Market Capitalization: $117.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Biodesix MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.97% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.43
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$203,017 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.66) to ($0.51) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

Medical Sector

892nd out of 969 stocks

Medical Laboratories Industry

22nd out of 25 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Biodesix.

3.0

Short Interest

Percentage of Shares Shorted
1.97% of the float of Biodesix has been sold short.
Short Interest Ratio / Days to Cover
Biodesix has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biodesix has recently increased by 27.06%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Biodesix does not currently pay a dividend.
Dividend Growth
Biodesix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BDSX.

1.9

News and Social Media Coverage

News Sentiment
Biodesix has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Biodesix this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biodesix insiders have bought 1,398.17% more of their company's stock than they have sold. Specifically, they have bought $203,017.00 in company stock and sold $13,551.00 in company stock.
Percentage Held by Insiders
63.80% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 21.24% of the stock of Biodesix is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biodesix are expected to grow in the coming year, from ($0.66) to ($0.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biodesix is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biodesix is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biodesix has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Biodesix (NASDAQ:BDSX) Stock

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

BDSX Price History

30 days | 90 days | 365 days | Advanced Chart

BDSX Stock News Headlines

September 7, 2023 | finance.yahoo.com

Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

August 26, 2023 | finance.yahoo.com

Jack Schuler Spends US$217k On Biodesix Stock

September 28, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

August 22, 2023 | finance.yahoo.com

Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

August 9, 2023 | finance.yahoo.com

Biodesix, Inc. (NASDAQ:BDSX) Q2 2023 Earnings Call Transcript

August 1, 2023 | finance.yahoo.com

Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference

July 26, 2023 | finance.yahoo.com

Biodesix (NASDAQ:BDSX) investors are sitting on a loss of 49% if they invested a year ago

July 24, 2023 | finance.yahoo.com

Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023

September 28, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

July 12, 2023 | finance.yahoo.com

Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

July 6, 2023 | finance.yahoo.com

Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

June 27, 2023 | finance.yahoo.com

Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier

June 1, 2023 | finance.yahoo.com

Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting

May 31, 2023 | finance.yahoo.com

Biodesix to Participate in William Blair’s 43rd Annual Growth Stock Conference

May 28, 2023 | finance.yahoo.com

Jack Schuler Spends US$65k On Biodesix Stock \

May 25, 2023 | finance.yahoo.com

Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing

May 18, 2023 | finance.yahoo.com

Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

May 11, 2023 | finance.yahoo.com

Biodesix Announces First Quarter 2023 Results and Highlights

May 11, 2023 | finance.yahoo.com

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

April 27, 2023 | finance.yahoo.com

Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023

April 12, 2023 | finance.yahoo.com

Insiders of Biodesix, Inc. (NASDAQ:BDSX) must be frustrated after market cap dropped US$16m since recent purchases

March 15, 2023 | finance.yahoo.com

Bullish Biodesix, Inc. (NASDAQ:BDSX) insiders filled their treasuries with US$34m worth of stock over last year

March 8, 2023 | finance.yahoo.com

Biodesix, Inc. (NASDAQ:BDSX) Q4 2022 Earnings Call Transcript

March 6, 2023 | finance.yahoo.com

Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights

March 6, 2023 | finance.yahoo.com

Biodesix, Inc. (BDSX) Reports Q4 Loss, Misses Revenue Estimates

February 21, 2023 | finance.yahoo.com

Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

February 16, 2023 | finance.yahoo.com

Even after rising 15% this past week, Biodesix (NASDAQ:BDSX) shareholders are still down 39% over the past year

See More Headlines

Receive BDSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.

BDSX Company Calendar

Last Earnings: 8/07/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BDSX
CUSIP: N/A
CIK: 1439725
Web: www.biodesix.com
Phone: 303-417-0500
Fax: N/A
Employees: 245
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-65,450,000.00
Net Margins: -158.72%
Pretax Margin: -158.72%
Return on Equity: -1,628.23%
Return on Assets: -79.00%

Debt

Debt-to-Equity Ratio: 5.51
Current Ratio: 0.90
Quick Ratio: 0.90

Sales & Book Value

Annual Sales: $38.21 million
Price / Sales: 3.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.27 per share
Price / Book: 5.70

Miscellaneous

Outstanding Shares: 78,610,000
Free Float: 28,458,000
Market Cap: $121.06 million
Optionable: Not Optionable
Beta: 1.25

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Scott Hutton (Age 51)
Pres, CEO & Director
Comp: $632k

Ms. Robin Harper Cowie (Age 43)
CFO, Sec. & Treasurer
Comp: $390.87k

Dr. Heinrich Röder
Founder & CTO

Mr. Christopher Vazquez
VP, Controller & Chief Accounting Officer

Mr. Jeffrey A. Bojar
VP of Legal and Regulatory Affairs

Mr. Mark DeBlock
VP of Sales

Mr. Robbie Lunt
Sr. Director of Marketing

Ms. Molli Halvorson
Director of HR

Dr. Gary Anthony Pestano Ph.D. (Age 56)
Chief Devel. Officer

Ms. Bobbi Coffin
Chief Growth Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BDSX Stock - Frequently Asked Questions

Should I buy or sell Biodesix stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BDSX shares.
View BDSX analyst ratings or view top-rated stocks.
How have BDSX shares performed in 2023?: Biodesix's stock was trading at $2.30 at the start of the year. Since then, BDSX stock has decreased by 33.0% and is now trading at $1.54.
View the best growth stocks for 2023 here.
Are investors shorting Biodesix?: Biodesix saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 229,600 shares, an increase of 27.1% from the August 31st total of 180,700 shares. Based on an average daily trading volume, of 68,400 shares, the short-interest ratio is currently 3.4 days. Currently, 2.0% of the company's shares are short sold.
View Biodesix's Short Interest.
When is Biodesix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our BDSX earnings forecast.
How were Biodesix's earnings last quarter?: Biodesix, Inc. (NASDAQ:BDSX) released its earnings results on Monday, August, 7th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. The firm earned $11.87 million during the quarter, compared to analysts' expectations of $11.38 million. Biodesix had a negative trailing twelve-month return on equity of 1,628.23% and a negative net margin of 158.72%.
What guidance has Biodesix issued on next quarter's earnings?: Biodesix updated its FY 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $52.00 million-$55.00 million, compared to the consensus revenue estimate of $53.18 million.

When did Biodesix IPO?: (BDSX) raised $76 million in an initial public offering (IPO) on Wednesday, October 28th 2020. The company issued 4,200,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
What is Biodesix's stock symbol?: Biodesix trades on the NASDAQ under the ticker symbol "BDSX."
Who are Biodesix's major shareholders?: Biodesix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Worth Venture Partners LLC (1.61%), Wells Fargo & Company MN (1.07%), BlackRock Inc. (0.52%), Geode Capital Management LLC (0.47%), Legato Capital Management LLC (0.45%) and State Street Corp (0.35%). Insiders that own company stock include Charles M Watts, Chris Vazquez, Gary Anthony Pestano, Hany Massarany, Jack W Schuler, John Patience, Kieran O'kane, Matthew Strobeck, Robert William Georgantas III, Robin Harper Cowie, Ryan H Siurek and Scott Hutton.
View institutional ownership trends.
How do I buy shares of Biodesix?: Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biodesix's stock price today?: One share of BDSX stock can currently be purchased for approximately $1.54.
How much money does Biodesix make?: Biodesix (NASDAQ:BDSX) has a market capitalization of $121.06 million and generates $38.21 million in revenue each year. The company earns $-65,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.
How many employees does Biodesix have?: The company employs 245 workers across the globe.
How can I contact Biodesix?: The official website for the company is www.biodesix.com. The company can be reached via phone at 303-417-0500 or via email at chris.brinzey@westwicke.com.

This page (NASDAQ:BDSX) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial